Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of VIB9600 in Healthy Subjects
NCT03621605Phase 1Terminated
- Sponsor
- Amgen
- Start
- Aug 2018
- Primary completion
- Apr 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VIB9600 in autoimmune diseases (3 arms), sponsored by Amgen. Primary endpoint: Safety and Tolerability at 113 days. Started Aug 2018; status: terminated.
02
Drugs
VIB9600
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT03621605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621605.